Table 3.
Cumulative exposure duration to chlormethine gel and other treatments ≥5% post-enrollment (n = 298)
| Treatment received by patients | For any time | For ≥3 months | For ≥6 months | For ≥12 months | For ≥24 months |
|---|---|---|---|---|---|
| Chlormethine gel | 298 (100) | 264 (88.6) | 234 (78.5%) | 190 (63.8) | 134 (45.0) |
| Skin-directed therapy | 232 (77.9) | 216 (72.5) | 206 (69.1) | 198 (66.4) | 155 (52.0) |
| Corticosteroids, topical | 179 (60.1) | 168 (56.4) | 160 (53.7) | 156 (52.3) | 120 (40.3) |
| Other topical | 31 (10.4) | 26 (8.7) | 24 (3.0) | 24 (8.1) | 17 (5.7) |
| Phototherapy | 61 (20.5) | 54 (18.1) | 54 (18.1) | 50 (16.8) | 36 (12.1) |
| Retinoids, topical, bexarotene | 17 (5.7) | 14 (4.7) | 14 (4.7) | 12 (4.0) | 7 (2.3) |
| Systemic therapy | 90 (30.2) | 82 (27.5) | 78 (26.2) | 66 (21.8) | 48 (16.1) |
| Other systemic | 25 (8.4) | 14 (4.7) | 13 (4.4) | 11 (3.7) | 8 (2.7) |
| Retinoids, systemic, bexarotene | 48 (16.1) | 44 (14.8) | 41 (13.8) | 35 (11.7) | 25 (8.4) |
Data are presented as n (%)